Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00211315 · ClinicalTrials.gov registry record · Phase 2
Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)
A Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT00211315: Completed Phase 2 study, sponsored by Manhattan Eye, Ear & Throat Hospital.
NCT00211315 is a Phase 2 study that has completed, run by Manhattan Eye, Ear & Throat Hospital. The registered enrollment target is 4 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00211315, a Phase 2 study, has completed, sponsored by Manhattan Eye, Ear & Throat Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
Congenital Telangiectasia or Coat's disease is an uncommon disorder that involves the growth of blood vessels of the macula. These blood vessels msy extend beneth the retina to produce an area of sub-retinal neovascularization(growth of abnormal blood vessels under the retina which "leak" fluid, causing reduction in vision). Limited forms of treatment are available in managing the neovascularization and its consequences. Anecortave Acetate injection will be considered as an attempt to control the growth of the abnormal blood vessels.
Interventions
- DRUG anecortave acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2002-03 |
| Est. Completion | 2007-03 |
| Phase | Phase 2 |
What the finished NCT00211315 record still lists
NCT00211315 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which anecortave acetate is the first listed.
NCT00211315 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00211315 about?
NCT00211315 is a clinical study titled "Treatment of Congenital Telangiectasia (Coat's Disease) With Open-label Anecortave Acetate (15mg.)". Congenital Telangiectasia or Coat's disease is an uncommon disorder that involves the growth of blood vessels of the macula. These blood vessels msy extend beneth the retina to produce an area of sub-retinal neovascularization(growth of abnormal blood vessels under the retina which "leak" fluid, cau...
What is the current status of trial NCT00211315?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2002-03. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00211315?
The interventions under investigation include: anecortave acetate (DRUG).
Who is sponsoring clinical trial NCT00211315?
This trial is sponsored by Manhattan Eye, Ear & Throat Hospital, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00211315's enrollment target sits among peer trials
4 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia